That's been an atypical source. So if a year ago you had asked me where do you think you're going to be able to acquire some of these assets I would not necessarily have picked that group out. But it's interesting that it is a very receptive discussion right now. We also reach out to sort of the traditional folks. We have a couple of conversations going on with universities as well as one with a large pharma where they're looking to monetize an asset that's not core to their business. We have seen a couple more of those than we've seen in past years, particularly with all the M&A activity in big pharma where A buys B. They bought it for a bunch of products and in the mix is some royalty from something and they want to monetize it. In some cases, to defray [ph] their acquisition cost.

Sapna Srivastava - Goldman Sachs

Then we think about the different structures you're describing, what falls under it? What kind of – you described some companies, universities, big pharma. And I guess what are they trying to do? Are they trying to sell you a part of the royalty stream and so you have to – how does that get extended? What kind of revenue stream can it bring you?

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)